Addition of the immunotherapy drug pembrolizumab (Keytruda) to standard of care for patients with advanced soft tissue sarcoma of the limb significantly improved disease-free survival, according to the results of the SU2C-SARC032 clinical trial led by researchers from the University of Pittsburgh, UPMC, Duke University, and Princess Margaret Cancer Centre.
The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute has been approved for research funding by the Patient-Centered Outcomes Research Institute to study whether adding chemotherapy before standard treatment with immunotherapy, radiation, and surgery for certain sarcomas will reduce the risk of the cancer returning.
